Clinical development of biosimilars: An evolving landscape

Bioanalysis

Volumn 5, Issue 5, 2013, Pages 575-586

  Subramanyam, Meena ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAEON; BIOSIMILAR AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPO HEXAL; HUMAN GROWTH HORMONE; INSULIN; ISOPHANE INSULIN; MARVEL INSULIN; NEUTRAL INSULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ALPHA INTERFERON AD; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; WEPOX; XM 02;

ANEMIA; ANTIBODY PRODUCTION; ANTIBODY TITER; AREA UNDER THE CURVE; BIOEQUIVALENCE; BIOMEDICINE; BLOOD AUTOTRANSFUSION; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PHARMACODYNAMICS; PRACTICE GUIDELINE; RENAL ANEMIA; REVIEW; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; GOVERNMENT REGULATION; GRANULOCYTE COLONY-STIMULATING FACTOR; GUIDELINES AS TOPIC; HUMAN GROWTH HORMONE; HUMANS; IMMUNOGENETIC PHENOMENA; INSULIN; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY;

EID: 84874138394     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.5     Document Type: Review

References (42)

1. Crommelin DJ, Bermejo T, Bissig M et al. Pharmaceutical evaluation of biosimilars: Important differences from generic low-molecular weight pharmaceuticals. Eur. J. Hosp. Pharm. Sci. 1, 11-17 (2005).
2. Knox S. The saga of the legal framework for biogenerics in Europe. J. Generic Medicines 2(2), 105-110 (2005).
3. Schneider CK, Borg JJ, Ehmann F et al. In support of the European Union Biosimilar framework. Nat. Biotechnol. 30(8), 745-748 (2012).
4. Berkowitz SA, Engen JR, Maze Jr. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11(7), 527-540 (2012).
5. Birkett DJ. Generics - equal or not? Aust. Prescr. 26, 85-87 (2003). (Pubitemid 36934873)
6. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1: Considering consequences of the immune response to a protein. BioPharm Int. November (2004).
7. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 2: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int. December (2004).
8. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 3: Effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. BioPharm Int. January (2005).
9. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 21(Suppl. 5), v9-v12 (2006). (Pubitemid 44391026)
10. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20(Suppl. 6), vi3-vi9 (2005).
11. Porter S. Human immune response to recombinant human proteins. J. Pharm. Sci. 90(1), 1-11 (2001). (Pubitemid 32050471)
12. Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol. Sci. 23(6), 254-256 (2002). (Pubitemid 34655726)
13. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3(4), 349-360 (2002). (Pubitemid 35364009)
14. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. N. Engl. J. Med. 358(11), 1109-1117 (2008). (Pubitemid 351398485)
15. Casadevall N, Rossert J. Importance of biologic follow-ons: Experience with EPO. Best Pract. Res. Clin. Haematol. 18(3), 381-387 (2005). (Pubitemid 40425350)
16. Gershon SK, Luksenburg H, Coté TR et al. Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. 346, 1584-1585 (2002).
17. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract. Res. Clin. Haematol. 18(3), 473-480 (2005). (Pubitemid 40425360)
18. Haag-Weber M, Eckardt KU, Hörl WH et al. Safety, immunogenicity and efficacyof subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, double-blind study. Clin. Nephrol. 77(1), 8-17 (2012).
19. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 74, 1617-1622 (2008).
20. Schellekens H. Assessing the bioequivalence of biosimilars: The Retacrit® case. Drug Discov. Today 14(9-10), 495-499 (2009).
21. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004).
22. Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 39(3-4), 364-375 (2005).
23. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for the detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
24. Nomura H, Imazeki I, Oheda M et al. Purification and characterization of human granulocyte-colony stimulating factor (G-CSF). EMBO J. 5(5), 871-876 (1986)
25. Souza LM, Boone TC, Gabrilove J et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 232(4746), 61-65 (1986). (Pubitemid 16037976)
26. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr. Opin. Hematol. 9(3), 183-189 (2002). (Pubitemid 34275963)
27. Gascon P, Fuhr U, Sorgel F et al. Development of a new G-CSF product based on biosimilarity assessment. Ann. Oncol. 21(7), 1419-1429 (2010).
28. Waller CF. Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia. Biosimilars 2, 1-11 (2012).
29. Cutfield WS, Lundgren F. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age. Horm. Res. 71(Suppl. 1), 39-45 (2009).
30. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 19(Suppl. 2), ii1-ii47 (2004).
31. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer 43(2), 258-270 (2007). (Pubitemid 46127840)
32. Deicher R, Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: A guide to selection for anaemia of chronic kidney disease. Drugs 64(5), 499-509 (2004). (Pubitemid 38338727)
33. Storring PL, Tiplady RJ, Gaines Das RE et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol. 100(1), 79-89 (1998). (Pubitemid 28051844)
34. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: An analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 25(7), 954-962 (2005). (Pubitemid 40917928)
35. Park S, Patel K, Ko J et al. Analytical comparisons of erythropoietin products from Korea and Amgen's Epogen® (epoetin alfa). Nephrol. Dial. Transplant. 21, iv14 (2006).
36. Deechongkit S, Aoki KH, Park SS et al. Biophysical comparability of the same protein from different manufacturers: A case study using Epoetin alfa from Epogen® and Eprex®. J. Pharm. Sci. 95(9), 1931-1943 (2006). (Pubitemid 44433025)
37. Schellekens H. Biosimilar epoetins: how similar are they? Eur. J. Hosp. Pharm. Sci. 3, 43-47 (2004).
38. Bennett CL, Luminari S, Nissenson ARet al. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351(14), 1403-1408 (2004). (Pubitemid 39288166)
39. Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J. Am. Soc. Nephrol. 16(Suppl. 1), S67-S69 (2005). (Pubitemid 41725087)
40. Schönholzer C, Keusch G, Nigg L, Robert D, Wauters J-P. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases. Nephrol. Dial. Transplant. 19(8), 2121-2125 (2004). (Pubitemid 39139647)
41. Banting FG, Best CH, Collip JB et al. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12(3),141-146 (1922).
42. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations - a cause for concern? Diabetes Technol. Ther. 14(11), 989-996 (2012).